Navigation Links
Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
Date:1/18/2011

e, including a blinded expert review of the flow-volume loops data from the healthy subject study as further evidence that there appears to be no consistent pattern suggestive of airway obstruction in these subjects.  Alexza also provided an analysis showing that there is no meaningful temporal relationship between placebo administration and decreases in FEV1.  Alexza believes this evidence and analysis confirms that the changes seen were likely background events in the population studied, where the repeated and extensive pulmonary function testing may have contributed to some of the observations.  Additionally, Alexza showed that the aerosol characterization does not indicate a basis for concern.  The Agency asked that Alexza reiterate these arguments in its resubmission.

In the information package, Alexza also showed that the pulmonary safety program in subjects with asthma and COPD had identified patients who may be susceptible to bronchospasm, the nature of this event, how it can be managed, and that Alexza believed the risk in these patients could be mitigated through labeling and a Risk Evaluation and Mitigation Strategy (REMS) program.  At the End-of-Review meeting, the Agency stated that it would be reasonable to propose a REMS program for the use of Staccato loxapine, and requested that as part of the Company's resubmission, Alexza provide a detailed REMS proposal including labeling, a medication guide, a communication plan, and post-approval studies to manage the potential risks.  In the resubmission Alexza must also show how to identify patients at risk of developing pulmonary side-effects, as well as a way to decide who should and should not be treated with Staccato loxapine when they present for treatment.

The FDA stated in the meeting minutes that it would likely present the AZ-004 application to an Advisory Committee.  Alexza believes that the AZ-004 NDA is a Class 2 resubmission and the r
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
2. Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
3. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
4. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
7. Alexzas Staccato® Nicotine Licensed to Cypress Bioscience
8. Alexza Pharmaceuticals to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
9. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
10. Alexza to Announce 2010 Second Quarter Financial Results on Monday, July 26, 2010
11. Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Calif. , July 28, 2014 ... leader in lifestyle healthcare and subsidiary ... that it has acquired Physician Recommended Nutriceuticals (PRN) ... omega-3s, and related products for dry ... Plymouth Meeting, PA, in a transaction worth up ...
(Date:7/28/2014)...  ResMed (NYSE: RMD ), an innovator ... sleep-disordered breathing and other chronic respiratory conditions, has won ... against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), ... 210 and 220 masks.  The judgment was entered by ... , is appealable, and applies throughout Germany.  ...
(Date:7/28/2014)... CHAPEL HILL, N.C. , July 28, 2014 /PRNewswire/ ... results of a clinical trial demonstrating that CXL-1427, a ... was well tolerated in healthy volunteers. The company has ... failure in a Phase IIa clinical trial designed to ... as its dosing levels. The Phase I ...
Breaking Medicine Technology:ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2
... Delaware, October 10, 2011 As the ... gigabytes of health and health-related technology information, and the ... providers are going to adopt new patterns to successfully ... reimbursement processes. In order to cope with ...
... Pharma, Inc. (Zosano) and Asahi Kasei Pharma Corporation (AKP) ... strategic collaboration for the development, commercialization and supply of ... AKP,s formulation of human parathyroid hormone (human PTH 1-34), ... risk of fracture.  Under the terms ...
Cached Medicine Technology:MedicalBillersandCoders.com Registers a Surge in Outsourcing of Physicians' Billing Requirements 2MedicalBillersandCoders.com Registers a Surge in Outsourcing of Physicians' Billing Requirements 3MedicalBillersandCoders.com Registers a Surge in Outsourcing of Physicians' Billing Requirements 4Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis 2Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis 3Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis 4
(Date:7/29/2014)... Seattle, Wa (PRWEB) July 29, 2014 Gout ... standards of lifestyles have proven that last statement essentially ... However, what many people still do not have are the ... not only is it costly to maintain treatment for it, ... hamper one’s daily activities to a grinding halt. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Consilium Staffing, Your ... year-over-year at the halfway point of 2014, with strong indications ... the second half of this year. , “This is a ... Vice President of Consilium Staffing. , “We are proud ... the year, but we are even more excited about how ...
(Date:7/29/2014)... Guests at Napa Valley's quintessential luxury resort, ... sleep experience. The top of each luxurious resort bed is ... These expertly crafted, 100% Egyptian cotton white duvets and pillow ... upon closer look, words are woven in the linens that ... , Intentional breathing and visualization are keys to ...
(Date:7/29/2014)... 29, 2014 A Forever Recovery , ... off to a great start and gives them a solid ... sponsor of the National Cherry Festival kickoff concert held on ... which was co-sponsored by Miller Lite and in partnership with ... Pepsi Bay Side Music Stage presented by Blue Cross Blue ...
(Date:7/29/2014)... Recently, Stwd.co.uk, a distinguished online supplier of special ... dresses . As a summer special offer, all these new ... percent off. All new and old customers can enjoy the ... to announce the new evening outfits. They want to bring ... happy to launch the big sale. Our cheap evening dresses ...
Breaking Medicine News(10 mins):Health News:Gout Natural Remedy Report Review | The Ultimate Secret to Eliminating Gout Naturally – Vinamy.com 2Health News:Consilium Staffing Experiences Significant Revenue Growth 2Health News:Auberge Du Soleil Offers INTENTIONS™ by Peacock Alley on Guests' Beds Providing a Unique Sleep Experience 2Health News:A Forever Recovery Sponsors National Cherry Festival Kickoff Concert Featuring Collective Soul on July 5 in Traverse City, MI 2Health News:Cheap Prom Dresses Available At Popular Online Store Stwd.co.uk 2
... ... , ... 22, 2010 -- DonJoy Velocity ankle braces were the best selling ankle brace ... ankle braces were double that of other ankle supports sold on the site., , , ...
... finds people are more likely to strike forefoot first, easing impact ... $100 on a fancy pair of running shoes, this news may ... for your body because of the way your feet land on ... course. Even so, "the way barefoot runners use their feet and ...
... ... months, numerous prominent politicians along with TV stars and sports heroes have made headline ... supporters cannot seem to get enough of the tawdry details of the betrayers, the ... lives. The true heroes are left standing in the shadows of their betrayers. ...
... , CALIFANO CONTINUES AS CHAIRMAN , ... Addiction and Substance Abuse (CASA) at Columbia University announced today ... Edmund S. Muskie School of Public Service, will become President ... succeeding Joseph A. Califano, Jr. , the former U.S. Secretary of ...
... , , NEW YORK , Jan. 27 ... $250,000 grant to the Clinton Health Access Initiative (CHAI), a ... in 2002. The grant will ensure the continuation of HIV/AIDS ... of the devastating January 12 earthquake. , ...
... or the woman who suggests using a condom makes no ... the woman suggests it makes a difference. If she highlights ... an erotic and fun activity, other women judge her more ... a condom or shares her concerns about sexually transmitted infections. ...
Cached Medicine News:Health News:DonJoy Velocity Ankle Brace is the Best Selling Ankle Brace in 2009 2Health News:Barefoot Best for Running? 2Health News:Barefoot Best for Running? 3Health News:The True Hero Stands in the Shadow of the Betrayer 2Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 2Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 3Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 4Health News:Ford Foundation Commits $250,000 to Support HIV/AIDS Services in Haiti 2Health News:Condom or no condom? It's not what you say, it's how you say it 2
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
... therapeutic, expandable turning surface for the BariMaxx™ ... Prevention and treatment of pressure ulcers, Large ... patients using a statuc mattress that would ... whose body weight and size pose a ...
... full-featured healthcare bed system providing a comfortable, ... management of larger patients, ,INDICATIONS: ,Large ... patients at risk for pressure ulcers, ... lbs. (including accessories), ,PRECAUTION: ,Side Rails ...
... beds feature folding head end and foot end deck ... head end and foot end deck panels folded the ... 67". This compact length makes storage, delivery and pick ... is not available on Model 4748B, Basic Maxi Rest ...
Medicine Products: